Lycopene and flow mediated dilatation index and blood pressure

The effect of lycopene supplementation on lipid profile and flow mediated dilatation index and blood pressure in patients with ischemic heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210614051574N4

Enrollment

Registered

2021-09-02

Start date

2021-09-22

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Heart failure

Interventions

Intervention 1: Intervention group: Patients in this group will receive lycopene tablets made by Vitabiotics company once a day for 8 weeks. Variables will be measured before and after taking the medi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The person's desire to participate in the project Heart failure due to myocardial infarction with a ejection fraction below 40% Having a body mass index between 18.5 to 30

Exclusion criteria

Exclusion criteria: Suffering from autoimmune, respiratory, acute phase of cancer or surgery, infectious and liver diseases and diabetes Having other heart diseases Taking corticosteroid and immunosuppressive drugs Consumption of supplements with antioxidant properties

Design outcomes

Primary

Measure	Time frame
Flow mediated dilatation index. Timepoint: Before and 8 weeks after interventions. Method of measurement: Ultrasound.;Blood pressure. Timepoint: Before and 8 weeks after interventions. Method of measurement: Blood pressure monitor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Sadeghi

Esfahan University of Medical Sciences

parsa.alinezhad85@gmail.com+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 11, 2026